BioOncology Watch

Timely Information for Practicing Physicians

 

FEBRUARY 2002

Non-Hodgkin's Lymphoma (NHL)

CHOP plus rituximab vs. CHOP alone.  In Phase II studies rituximab in combination with CHOP chemotherapy was well tolerated and induced responses in >90% of patients with indolent or aggressive lymphoma.  As a result, a multicenter, randomized trial to compare CHOP (cyclophosphamide 750 mg/m2 on day 1, doxorubicin 50 mg/m2 on day 1, vincristine 1.4 mg/m2, and prednisone 40 mg/m2 for 5 days every 3 weeks) plus rituximab (375 mg/m2 on day 1 of each cycle) to CHOP alone (8 cycles) in elderly (60 to 80 years old) previously untreated patients with diffuse large B-cell lymphoma was conducted by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) in France, Belgium, and Switzerland (N=399).  The complete response (CR) rate was greater in the CHOP plus rituximab group (76% vs 63%; p=0.005).  Event-free survival was longer in patients treated with CHOP plus rituximab (p<0.001) and the 2-year survival rate was 70% compared to 57% for those treated with CHOP alone (p=0.007).  Adverse experiences were similar in the two treatment groups.  These data indicate that the addition of rituximab to CHOP increases the CR rate and prolongs survival in elderly patients with diffuse large B-cell lymphoma.  An accompanying editorial by Bruce Cheson concluded that these results are exciting but cautioned that they need to be confirmed (a large US trial of CHOP vs CHOP plus rituximab has recently been completed and is undergoing analysis) and that longer follow-up is required to show that the advantage conferred by rituximab persists.  (Coiffer B, et al. N Engl J Med 2002; 346:235-242 and Cheson B. N Engl J Med 2002;346:280-282)

 

B-Cell Chronic Lymphocytic Leukemia (CLL)

CD20 levels and response to rituximab.  Complement-dependent cytotoxicity is thought to be an important mechanism of action for rituximab.  Josee Golay and colleagues showed that the level of CD20 expressed in cells isolated from patients with B-CLL, prolymphocytic leukemia, and mantle cell lymphoma (as measured by immunofluorescence or calibrated beads) correlated linearly with lytic response to rituximab and complement in vitro.  Although CD55 and CD59 levels did not predict susceptibility to complement, blocking both CD55 and CD59 increased lysis 5- to 6-fold in B-CLL samples responding poorly to rituximab.  Thus, these data show that CD20, CD55, and CD59 are important determinants of response to rituximab and complement in vitro.  Other factors may be important as previous investigations (Weng W-K and Levy R. Blood 2001;98:1352-1357) have not found the expression of CD55 and CD59 or in vitro susceptibility to complement-mediated lysis to predict clinical outcome to rituximab. (Golay J, et al. Blood 2001;98:3383-3389)

 

Neuroblastoma (NB)

Anti-GD2 monoclonal antibody therapy.  The activation of complement by 3F8 (a murine IgG monoclonal antibody directed against the ganglioside GD2) may mediate the destruction of neuroblasts observed in vitro.  Brian Kushner and coworkers conducted a phase II study in NB patients who were incomplete responders to intensive chemotherapy and were treated with 3F8 (10 mg/m2/day intravenous infusion on days 6-10 and 13-17) combined with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). Twelve (80%) of 15 patients with bone marrow refractory disease achieved a CR and 3 other patients had prolonged progression-free survival (12 to 21+ months).  Five of 10 patients with recurrent NB had CRs in bone marrow.  However, 15 patients with bulky progressive disease continued to progress through 3F8/GM-CSF treatments (although 2 patients did have scintographic findings suggestive of a transient response). These preliminary findings suggest that 3F8/GM-CSF treatments are potentially effective therapy for minimal residual NB in bone marrow. (Kushner BH, et al. J Clin Oncol 2001;19:4189-4194)

 

Chronic Myelogenous Leukemia (CML)

Effect of pretransplant interferon (IFN) therapy.  The impact of prior IFN therapy on allogeneic transplantation outcome is unclear.  In a previous study limited to recipients of unrelated bone marrow, IFN was found to have an adverse effect on survival if it had been given for >6 months before transplantation (Morton AJ, et al. Blood 1998;92:394-401).  Stephanie Lee and associates reviewed data on 740 patients who had received unrelated donor transplants for CML in first chronic phase provided by the International Bone Marrow Transplant Registry and the National Marrow Donor Program.  Prior IFN had been administered to 489 (66%) patients while 251 (34%) patients had not been exposed to IFN.  Disease characteristics for the two groups were similar at diagnosis.  No effect of IFN exposure was detected for overall survival, leukemia-free survival, nonrelapse mortality, engraftment, relapse, or acute/chronic graft-versus-host disease.  Thus, this retrospective review failed to uncover an adverse effect of prior IFN therapy on the outcome of unrelated donor transplantation.  (Lee SJ, et al. Blood 2001;98:3205-3211)

 

Transplantation

Nonablative allogeneic hematopoietic transplantation.  Issa Khouri et al performed a pilot study of combination therapy with fludarabine and cyclophosphamide given at conventional non-myeloablative doses in 20 consecutive patients with recurrent follicular or small-cell lymphocytic lymphoma (9 patients also received rituximab).  Twelve patients were in CR by the time of transplantation and all patients achieved engraftment of donor cells.  All patients achieved a CR and none have relapsed after a median follow-up of 21 months.  These early findings suggest that nonablative chemotherapy with fludarabine and cyclophosphamide followed by allogeneic stem cell transplantation is a promising therapy for patients with indolent lymphoma and further study is warranted.  (Khouri IF, et al. Blood 2001;98:3595-3599)

 

Return to Archive

Produced by Market Development Group through an educational grant from Genentech, Inc. and IDEC Pharmaceuticals. Comments and inquiries can be e-mailed to webmaster@biooncologywatch.org